PPIA and non-small cell lung carcinoma: To further clarify the clinical relevance of the CypA‐SLC7A11 axis in NSCLC chemoresistance, a cohort using specimens from 30 cases of NSCLC (see details in Table 3) was categorized into the responder or non‐responder group based on the sensitivity to chemotherapy.